6533b829fe1ef96bd128a5fe

RESEARCH PRODUCT

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Valter GatteiGian Matteo RigolinYair HerishanuAaron PolliackAnnalisa ChiarenzaFrancesca RossiFortunato MorabitoMarzia VarettoniPaolo SportolettiRoberta MurruRiccardo BombenGianluigi RedaGiovanni TripepiGiacomo LosetoLuca LaurentiGraziella D’. ArrigoAnnalisa BiagiAntonella ZucchettoAdalgisa CondoluciUgo ConsoliAntonio CuneoIlaria Del GiudiceDavide RossiAnna Grazia RecchiaFrancesco Di RaimondoRiccardo MoiaGiovanni Del PoetaRobin FoàGianluca GaidanoIlaria ScortechiniVincenzo FraticelliIlaria AngelettiDaniela PietrasantaAngela RagoCirino BottaMarta CosciaErnesto VignaFrancesca Romana MauroMassimo Gentile

subject

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness10.1038/s41375-020-0833-xhttp://hdl.handle.net/2318/1760439